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The decreased metastatic potential of
rhabdomyosarcoma cells obtained through MET
receptor downregulation and the induction of
differentiation
K Miekus1, E Lukasiewicz1, D Jarocha1, M Sekula1, G Drabik2 and M Majka*,1
Rhabdomyosarcoma (RMS) is the most common type of pediatric soft tissue sarcoma. The MET receptor has an important role in
the biology of RMS, and its overexpression and hyperactivation correlate with the metastatic ability of RMS. Consequently,
interfering with MET expression or functionality may constitute a sound strategy for reducing the progression and metastatic
potential of RMS. Our study reveals that downregulation of the MET receptor leads to changes in the morphology of ARMS cell
in vivo. Tumors acquire a spindle shape that is characteristic of muscle fibers. Inhibition of MET expression or function leads to
(i) a decreased expression of the early myogenic marker MyoD, (ii) a decreased ability of ARMS cells to metastasize to bone
marrow cavities, (iii) downregulation of CXCR4 receptor expression and (iv) a decreased migration of MET-depleted cells
towards gradients of HGF and SDF-1. Finally, we demonstrate that in vitro differentiation of alveolar RMS cells decreases their
metastatic behavior by reducing both the expression of the MET and CXCR4 receptors and their migratory response to HGF and
SDF-1. These findings suggest that blockers of MET receptor function and inducers of RMS cells differentiation may be clinically
useful for reducing the aggressiveness and metastatic potential of RMS and may have significant implications for its treatment.
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Rhabdomyosarcoma (RMS) is the most common type of
pediatric soft tissue sarcoma.1 On the basis of histopatholo-
gical features, RMS can be divided into four subtypes, with
embryonal RMS (ERMS) and alveolar RMS (ARMS) being
the most prevalent.2 Cases of ARMS exhibit a significantly
worse prognosis than ERMS case, as indicated by a higher
risk of both relapse and metastasis in ARMS cases. This poor
prognosis has been linked with the particular characteristic
of ARMS cells undergoing chromosomal translocation,
leading to the expression of the fusion proteins PAX3-FKHR
(t(2:13)(q35:q14)) and PAX7-FKHR (t(1:13)(p36:q14)). In
contrast, ERMS tumors do not carry a distinct genetic
lesion and generally follow a more favorable course;
however, a 11p15-loss of heterozygosity has been found in
some cases.3–7
The origin of RMS has yet to be fully elucidated. According
to one hypothesis, it develops from satellite cells,7 while a
contrasting theory proposes it has a mesenchymal origin.8,9
However, the common assumption is that the development of
this tumor is closely related to defects in the proper
differentiation of stem or progenitor cells.10
The MET receptor, encoded by MET proto-oncogene,
belongs to a family of growth factor receptors that have
intrinsic tyrosine kinase activity.11,12 MET activation by its
ligand, hepatocyte growth factor (HGF) (also known as scatter
factor), leads to pleiotropic effects in various target cell types,
including morphogenetic transformation, induction of cell
proliferation, cell motility and invasiveness under both normal
and pathological conditions.13 MET has been reported to be
overexpressed in a variety of human tumors, where it has a
crucial role in malignant transformation.14–16 Moreover, RMS
tumors have been shown to express the MET receptor, with
the ARMS subtype exhibiting the highest level of expres-
sion.17 It has been postulated that the deregulation of MET
activity is a key event underlying tumor metastasis,12,18 as its
overexpression and hyperactivation have been shown to
robustly correlate with the metastasis of epithelial cancer
cells,13 colon cancer cells19 and head and neck squamous
cancer cells.20 Intriguingly, the downregulation of MET
receptors on fibrosarcoma cells has also been reported to
reduce tumor growth, invasion, and motility.21 Additionally,
treatment with MET receptor inhibitors has been found to
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reduce tumor burden and decrease the metastasis of
ovarian,22,23 breast, lung and glioma tumor models.24
Hence, decreasing MET receptor expression or function-
ality may constitute a sound strategy for reducing the
progression andmetastasis of RMS. Our group demonstrated
previously that the downregulation of the MET receptor not
only reduces tumor growth but also reduces the short-term
engraftment potential of ARMS cells.25
The chemokine receptor CXCR4, expressed by RMS cells,
has also been found to affect the metastatic potential of this
tumor.26,27 Additionally, CXCR4 overexpression and hyper-
activation has been shown to correlate with the metastatic
ability of breast cancer cells.28 Consistent with this finding,
blocking of CXCR4 receptor expression inhibits tumor growth
in mouse models of breast cancer.29
A tumor can be regarded as a disease of cell differentiation.
However, the molecular mechanism that renders cells unable
to differentiate during carcinogenesis is not well understood
and most likely varies between tissue and cancer types.30
Several agents with the ability to induce differentiation have
been studied over the past few years, with some already in
clinical use.10,31,32
Previous research has not evaluated the influence of MET
receptor expression on RMS cell differentiation in detail.
Physiologically, MET is rapidly downregulated at the onset
of myogenic differentiation.33 Previously, Taulli et al.34
demonstrated that the re-expression of microRNA-206
(miR-206) in human RMS cells induces myogenic differentia-
tion and blocks tumor growth in xenograftedmice by switching
the global mRNA expression profile to one resembling that
of mature muscle. In the study, the authors postulated that
the differentiation process was connected to MET receptor
expression, underscoring its importance for RMS.
Because the MET and CXCR4 receptors have a key role
in the progression of RMS tumors, we evaluated the influence
of MET downregulation on the metastatic potential of
RMS cells, both in vivo and in vitro. Furthermore, because
rapid downregulation of the MET and CXCR4 receptors
takes place during the onset of myogenic differentiation,
we investigated how the differentiation of RMS cells
influences MET and CXCR4 receptor expression and
activation.
Results
MET-dependent differentiation of RMS cells in vivo. As
previously reported,25 NOD-SCID mice were injected with
two types of control cells (WT and shLacZ) as well as shMET
RH30 and SMS-CTR cells. Hematoxylin and eosin staining
revealed that the morphology of tumors derived from the
control cells of both subtypes differed significantly. The
tumors derived from control alveolar RH30 cells had a
disorganized and immature appearance (Figure 1a), while
the architecture of tumors from embryonal SMS-CTR cells
showed cell linings that were close to each other, similar to
muscle fibers (Figure 1b). Interestingly, the morphology of
tumors derived from shMET RH30 cells also resembled the
Figure 1 Histopathological, molecular and flow cytometry analysis of control and shMET ARMS and ERMS cells. The comparison of ARMS, RH30, (a) and ERMS, SMS-
CTR, (b) tumors derived from WT and shMET transduced RMS cells showed differences in morphology, Ki67 and desmin expression. (a) H&E staining (upper panel) revealed
that the morphology of MET-depleted ARMS tumors resembles the morphology of more differentiated ERMS tumors; Ki67-staining shows a reduced level of proliferation in
MET-depleted tumors (middle panel). MET-depleted tumors did not express desmin, suggesting they have a more mature phenotype (lower panel). (b) H&E staining (upper
panel) shows the spindle shaped morphology of ERMS tumors regardless of MET receptor expression; Ki67-staining shows a reduced proliferation rate (middle panel), and
these tumors did not express desmin (lower panel). (c) Western blot analysis of MyoD expression shows weak staining in SMS-CTR cells and complete downregulation of
MyoD expression in shMET RH30 cells. (d) Western blot analysis of MET tyrosine-phosphorylation shows a lack of MET receptor phosphorylation and a reduced level of total
MET and Src expression in shMET cells (upper panel). Flow cytometry analysis of the MET receptor expression (lower panel). Representative staining of one tumor out of six is
shown. Western blot and FACS analysis were performed at least three times with similar results. Representative results are shown
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morphology of the more mature and differentiated, spindle-
shaped SMS-CTR cells (Figure 1a). Immunohistochemical
examination revealed that control RH30 cells had a high
expression of desmin and Ki67, whereas tumors derived
from shMET RH30 cells were characterized by a lack of both
Ki67 and desmin expression (Figure 1a). SMS-CTR control
and shMET SMS-CTR cells did not exhibit expression of
these markers (Figure 1b).
As the morphology of tumors derived from shMET RH30
cells indicated a more differentiated phenotype, we investi-
gated the influence of MET receptor downregulation on the
expression of MyoD, a marker of undifferentiated muscle
cells. In contrast to control cells, shMET RH30 cells exhibited
a strong decrease in the expression of MyoD (Figure 1c). In
contrast, SMS-CTR cells showed a low expression of MyoD
regardless of MET receptor status (Figure 1c). These data are
the first to indicate that MET receptor expression may be
linked to the undifferentiated status of ARMS tumors.
Src kinase expression and activation have been linked to
MET receptor signaling. Therefore, we also investigated the
levels of MET-receptor phosphorylation and the expression of
Src kinase in the RH30 cell line. Phosphorylated MET protein
appeared as a very faint band in control cells and was absent
in shMET RH30 cells (Figure 1d). Unexpectedly, MET
receptor downregulation caused a strong decrease in Src
kinase expression. Using flow cytometry analysis to assess
the level of MET receptor downregulation in the RH30 cell line,
we found that expression was robustly decreased fromB85%
in control cells to B4% in shMET cells (Figure 1d).
MET-depleted cells exhibit a reduced ability to
metastasize to bone marrow (BM) in vivo. Our studies
of the metastatic potential of RH30 cells show that mice injected
intra subcutaneous (i.sc.) with control RH30 cells had
considerably more BM metastasis than mice injected with
shMET RH30 cells after 30 days of tumor growth. In mice
injected with control RH30 cells, 68% of legs examined had
BM micrometastasis. However, only 36% of the legs of animals
injected with shMET cells contained BM micrometastasis
(Figure 2a). The confirmation of the appearance of human
RMS cells in murine BM is presented in Figure 2b (tumor cells
were stained immunohistochemically) and in Supplementary
Figure 1 (tumor cells were detected by immunofluorescence).
These data suggest that MET receptor expression is important
for the metastatic process of RMS tumors.
Mouse hepatocyte growth factor does not activate
migration of human RMS cells. Even though recent
findings have revealed that mouse HGF is able to activate
human cells,35 some authors have postulated that murine
HGF does not activate human MET receptor.36,37 When we
examined phosphorylation levels of the AKT and MAPK
kinases, which are proteins involved in cell movement and
directional chemoattractant response, we observed kinase
activation after 5min. However, after 30 and 60min of
stimulation, AKT and MAPK were not phosphorylated
(Figure 3a). In addition, this short activation time of MET
receptor was not sufficient to cause either an invasion or
chemotaxis of RH30 cells toward a mouse HGF gradient
(Figures 3b and c).
Decrease of CXCR4 expression and signaling in MET
receptor-depleted cells. Because mouse HGF was insuffi-
cient to induce metastasis in RMS cells, we subsequently
looked for other surface receptors influenced by the
presence of MET receptor expression that could be
responsible for the decreased ability of RMS cells to engraft
to the BM of NOD-SCID mice. One receptor known to be
involved in RMS BM metastasis is CXCR4.26–28
To evaluate how MET receptor downregulation mediates
the expression and activation of the CXCR4 receptor, we used
MET-depleted cells to examine both CXCR4 expression and
activation. We found that cytofluorometric characterization of
shMET RH30 cells exhibited a decreased expression of the
CXCR4 receptor (Figure 4a). Downregulation of the MET
receptor also led to reduced phosphorylation of MAPK and
AKT following SDF-1 stimulation in ARMS cells (Figure 4b).
Moreover, the reduced expression of CXCR4 after MET
receptor downregulation correlated strongly with the severely
reduced chemotactic ability of RMS cells in response to a
SDF-1 gradient (Figure 4c). These results partially confirm our
hypothesis that CXCR4 may be responsible for the
BM micrometastasis of RMS cells.
Figure 2 BM metastatic ability of tumors derived from control and shMET cells.
(a) The graph shows the percentage of legs with and without metastasis in the
BM for control RH30 and shMET RH30 cells. Each point on the graph represents
one leg (WT–circle, shMET-square). These experiments were performed twice with
n¼ 6 and n¼ 5, giving the overall number of 22 legs for each group. The
results were combined and submitted to w2 analysis. w2, df¼ 4.464. *Po0.05.
(b) Immunohistochemistry of murine BM. Human RMS cells are visualized using
anti-vimentin staining. 600 magnification
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Inhibition of MET activation decreases CXCR4 expres-
sion and responsiveness to SDF-1 in RMS cells. Next,
we wanted to know whether blocking MET receptor activation
influences the expression and functionality of the CXCR4
receptor. To answer this question, we used the specific MET
receptor phosphorylation inhibitor, SU11274. To verify the
ability of SU11274 to block the activity of the MET receptor,
RH30 cells were stimulated with human HGF. The MET
receptor was phosphorylated on tyrosine 1234/1235 follow-
ing human HGF stimulation, whereas preincubation with
SU11274 strongly inhibited MET receptor phosphorylation
(Figure 5a left panel). As expected, downstream phosphor-
ylation of MAPK and AKT kinases by human HGF was also
decreased in inhibitor-treated cells (Figure 5a middle panel).
The level of total Src seemed to increase slightly after
SU11274 treatment; however, the phosphorylated form of
Src was undetectable both in the control and in SU11274-
treated cells (Figure 5a right panel). Interestingly, we
observed a significant decrease in CXCR4 receptor expres-
sion on the surface of RH30 cells following treatment with
SU11274 using flow cytometry analysis (Figure 5b). More-
over, we noticed that the morphology of the MET inhibitor-
treated cells changed, becoming more elongated and
spindle-shaped (Figure 5b). The phosphorylation of AKT
and MAPK kinases after SDF-1 stimulation was also inhibited
in the RH30 cells treated with SU11274 (Figure 5c). In
addition, we found defects in the chemotactic response of
treated cells to both SDF-1 and HGF gradients (Figure 5c).
At the same time, their proliferation potential remained
unchanged (data not shown). These findings further confirm
our in vivo data and clearly show that MET and CXCR4
expression has a functional role in the migration and
differentiation of RMS cells.
Differentiation of RMS cells causes decreased
expression and signaling of the MET and CXCR4
receptors. On the basis of our in vivo observation that
MET-depleted tumors were more differentiated and our
in vitro observation that murine C2C12 cell differentiation
led to loss of chemotactic responsiveness to a SDF-1
gradient (Supplementary Figure 2), we speculated that the
differentiation process influences the expression and/or
functionality of the MET and CXCR4 receptors. To confirm
our hypothesis, RH30 cells were subjected to differentiation.
During the differentiation process, the cells altered their
morphology, becoming elongated and spindle-shaped
(Figure 6a left panel). An analysis of muscle differentiation
markers revealed a decrease in the expression of MyoD and
an increase in the expression of myogenin (Figure 6a middle
panel). During the differentiation process, a significant
decrease in MET expression was observed, in conjunction
with a decrease in MET tyrosine phosphorylation and a slight
decrease in Src expression (Figure 6a right panel). Remark-
ably, we also observed a decrease in CXCR4 receptor
expression at both the mRNA (Figure 6b left panel) and
protein levels (Figure 6b right panel). Subsequent evaluation
of the migratory properties of differentiated RH30 cells
revealed a strong inhibition of human HGF- and SDF-
mediated migration (Figure 6c), which positively correlated
with the decreased expression of these receptors. These
data offer further evidence that MET receptor modulates
ARMS cell differentiation and strongly influences the meta-
static ability of ARMS cells.
Discussion
Despite recent advances, the prognosis for cases of RMS in
advanced metastatic stages is still bleak. In our study, we
examined how the downregulation of MET receptor expres-
sion and the induction of RMS cell differentiation affect the
metastatic potential of RMS cells. Our group25 and others34
have previously shown that MET downregulation causes a
decrease in the size of tumors derived from RMS cells
transplanted into NOD-SCID mice. These findings provide
further explanation for this mechanism that may be
Figure 3 Activation of RH30 cells by mouse HGF. (a) Western blot analysis of
AKT and MAPK phosphorylation following stimulation with different doses of mouse
HGF. Activation of AKT and MAPK kinases was observed after 5 min of stimulation
with mouse HGF at concentration levels of 50, 100 and 200 ng/ml. (b) In invasion
assays, RH30 cells did not exhibit any migratory responses through the Matrigel
towards a mouse HGF gradient (50, 100, 200 ng/ml). (c) RH30 cells did not show
any chemotactic activity towards murine HGF after stimulation with 50, 100 and
200 ng/ml of mouse HGF. Cells that migrated through pores in the membranes in
invasion and chemotaxis assays are indicated by white arrows. Bar¼ 50mm
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responsible for the reduction in tumor size. We demonstrate,
for the first time, that MET receptor downregulation, in
conjunction with the inhibition of HGF- induced MET activa-
tion, results in profound differentiation of ARMS tumor cells
in vivo. MET-depleted ARMS cells acquire the morphology of
the more differentiated spindle-shaped ERMS cells.
Our immunohistochemical analysis also confirmed that MET-
depleted tumors had a reduced proliferation potential (as
evidenced by the lack of Ki67 expression) and lacked expression
of the marker desmin. This lack of desmin expression was also
observed in SMS-CTR cells, regardless of MET expression.
Previous studies have found desmin expression in both alveolar
andembryonalRMS’s.38 Lackof desminwas found to bea signof
a less differentiated RMS type,39 and the later appearance of
desmin has been correlated with the differentiation process.40
However, there have also been reports showing that the
downregulation of desmin expression, as a result of chemother-
apy, correlates with morphological changes of RMS cells into
differentiated strap-like cells.41
Nevertheless, there are no published data evaluating the
expression of desmin in RMS-derived cultured cancer cell
lines. Our observation that the inhibition of HGF-MET
interactions through MET downregulation decreases desmin
expression extends recently published suggestions that HGF
may upregulate desmin expression in mesenchymal cells.42
Moreover, Anastasi et al.33 found that constitutive expression
of the MET receptor causes morphological changes and
prevents the differentiation of mouse satellite C2C12 cells.
Thus, our data suggest that the reduction in tumor size
following MET receptor downregulation is caused by the
induction of tumor cell differentiation. This result directly links
the expression of the MET receptor with the differentiation
status of RMS cells.
To examine whether downregulation of the MET receptor
influences the metastatic potential of RMS cells, NOD-SCID
mice were injected subcutaneously with both control cells and
MET-depleted RMS cells. After 30 days, the presence of
these cells in bone marrow, one of the primary sites of RMS
metastasis, was evaluated (Figure 2). Analysis revealed that
the downregulation of the MET receptor does significantly
reduce the metastasis of RH30 cells. These findings support
our previous data showing that downregulation of the MET
receptor expression inhibits the ability of RMS cells to engraft
into BM during short-term assays.25 Recently, the MET
receptor was also shown to have an important role in the
BM metastasis of breast cancer.43
Figure 4 Expression and function of the CXCR4 receptor in MET-depleted cell. (a) FACS analysis of CXCR4 staining in RH30 cells. A considerable decrease in the
expression of the receptor in shMET RH30 cells when compared with control cells was noted. (b) Western blot analysis of AKT and MAPK activation in shMET RH30 cells
showed a decrease in the phosphorylation of these kinases following stimulation with human HGF (20 ng/ml) and SDF-1 (10 ng/ml and 100 ng/ml). (c) Chemotaxis assay
showed a significant decrease in the cell migration of shMET RH30 cells towards both HGF and SDF-1 gradients when compared with control cells. *Po0.05
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Because previous studies,36,37 as well as our own
observations (Figure 3), suggest that human RMS cells do
not respond to murine HGF gradients in chemotactic assays
and murine HGF cannot stimulate the migration of human
RMS cells in an in vivo murine model, we speculated that a
different mechanism mediated the reduced metastatic ability
and lowered short-term engraftment potential of shMETRH30
cells.25
Our published data have revealed that the CXCR4 receptor
is an extremely potent inducer of RMS cell migration.26
Moreover, we have previously shown that this receptor is
expressed on murine satellite cells44 and our current research
indirectly indicates that CXCR4 receptor expression
decreases during differentiation of murine satellite cells
(Supplementary Figure 2). Interestingly, MET receptor activa-
tion is correlated with CXCR4 receptor expression in both
RMS and breast cancer cells.45,46
On the basis of these findings, we became interested in the
fate of the CXCR4 receptor in shMET RH30 cells. In this
study, we demonstrate that the downregulation of MET
receptor expression in RH30 cells causes a simultaneous
downregulation of CXCR4 receptor expression and reduces
its activity in these cells (Figure 4). To examine the
mechanism underlying the decrease in CXCR4 expression
and activation in MET-depleted cells, we used a specific
inhibitor of the MET receptor. We found that inhibiting MET
receptor activity was sufficient for decreasing the expression
and activation of the CXCR4 receptor in RH30 cells. Because
the viability and proliferation rates of treated and non-treated
RMS cells were similar, the defect in HGF and SDF-1
responsiveness was not due to a toxic effect of the MET
inhibitor.
Thus, for the first time we have demonstrated that the
functional MET receptor is necessary for the expression and
activation of CXCR4 in RMS cells. This finding indicates the
existence of a direct relationship between these two receptors
at the level of MET receptor activation. This finding also
indicates that the expression and activation of the CXCR4
receptor is tightly regulated through a signaling pathway that
is in turn regulated by MET receptor activation. Therefore, our
results are consistent with the previous report of Jankowski
et al.27 and further elucidate the relationship between theMET
and CXCR4 receptors in RMS cells.
Similar data regarding the interrelation between these two
receptors have been reported for both low and high invasive
breast carcinoma cells. HGF stimulation was shown to lead to
the activation of c-Src (signaling downstream of HGF/MET),
and depending upon the signaling pathway, resulted in the
activation or suppression of NF-kB and Ets1 transcription
factors, causing a subsequent increase or decrease of
CXCR4 expression, respectively.45 On the basis of these
observations, it seems probable that the relationship between
MET and CXCR4 in RMS cells is also connected with the
c-Src, NF-kB and Ets1 signaling pathways. Our results show
that the downregulation of MET receptor expression causes a
strong decrease in Scr expression and that the differentiation
of RMS cells also leads indirectly to a slight decrease in Scr
expression.
Figure 5 Negative influence of the MET inhibitor (SU11274) on CXCR4 signaling. (a) The expression of phospho-MET after human HGF stimulation of control cells.
Preincubation with SU 11274 abolished this phosphorylation. Phospho-MET was immunoprecipitated from 1mg of protein extracts with an anti-MET antibody. Corresponding
blots were developed after staining with anti-phospho-MET (Tyr 1234/1235) (left panel). Western blot analysis of AKT and MAPK activation in inhibitor treated cells showed a
reduced activation of these signaling pathways following stimulation with 20 ng/ml human HGF (middle panel). Western blot analysis of phospho-Src showed no expression of
this protein, whereas the total level of Src increased slightly after MET receptor inhibition using SU11274 (right panel). (b) Flow cytometry analysis of CXCR4 receptor
expression and morphology assessment after inhibitor treatment. RH30 cells were treated with 5mM of SU11274 for 16 h before experiments. The decrease in the level of
surface expression was observed and the changes in the morphology of SU11274-treated cells were noted. Cells became more elongated and resembled differentiating cells.
(c) The chemotactic analysis of RH30 cells. The ability of RH30 cells to migrate toward the human HGF (20 ng/ml) and SDF-1 (100 ng/ml) gradients was severely reduced after
SU11274 treatment (left panel). Western blot analysis of AKT and MAPK phosphorylation after SDF-1 stimulation (100 ng/ml) showed a reduced activation of these signaling
pathways following incubation with SU11274 (right panel). Western blot and FACS analysis was performed a minimum of three times and representative results are shown.
The chemotaxis assay was performed three times in duplicates. Bar¼ 50mm; *Po0.05
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In the case of RMS, other authors have linked the
expression of the MET and CXCR4 receptors to the
expression of the PAX3-FKHR fusion protein.46 On the basis
of our results, we cannot challenge the correlation between
the PAX3-FKHR transcription factor and the expression of the
MET and CXCR4 receptors. However, recent reports on the
effect of the direct binding of PAX3-FKHR to the CXCR4
promoter on CXCR4 expression have been questioned26,47
These studies reveal that binding of PAX3-FKHR to regions
other than the core promoter might be responsible for the
expression of PAX3-FKHR-dependent genes.47 Our data not
only corroborate this recent finding but also indicate that while
the presence of PAX3-FKHR is necessary, it is insufficient for
inducing CXCR4 expression without the concurrent activation
of the MET receptor.
We also examined the effect of differentiation on the
metastatic behavior of RMS cells. We observed an increased
expression of myogenin and MYHC2, as well as myostatin
(late muscles differentiation markers), in RH30, CW9019
RMS and C2C12 cells following the induction of differentiation
(Supplementary Figure 3). Furthermore, the induction of RMS
cell differentiation decreased the expression and activation of
the MET and CXCR4 receptors, both of which are important
for the metastatic ability of RMS tumors, especially the
alveolar subtype.26,27 The differentiation of RMS cells also
strongly reduced their metastatic ability and decreased their
migration toward HGF and SDF-1 gradients in vitro. Thus, for
the first time, we have shown that the differentiation of RMS
cells is directly connected with their ability to disseminate to
distant organs.
Because satellite cells express both the MET and CXCR4
receptors, akin to RMS cells, we induced the differentiation of
satellite cells and checked their ability to migrate toward HGF
and SDF-1 gradients. In both cases, a strong decrease in
migratory ability toward HGF or SDF-1 was observed. This
similarity suggests that ARMS development is more likely
linked to the differentiation defect of the satellite cells rather
than to the differentiation defect of the mesenchymal cells.
The role of MET receptor activation in the pathogenesis of
RMS has been well documented; however, the influence of
MET expression on the differentiation of RMS has not been
studied at all. Recent work by Taulli et al.34 showed that the
Figure 6 Decreased expression and signaling of the MET and CXCR4 receptors in differentiated RMS cells. (a) The morphology of RH30 cells under differentiation
inducing conditions. The differentiation process of RH30 cells was induced using low serum (2% HS) and TPA (100 nM). The cells were analyzed on days 4, 8 and 10.
Beginning on day 4, morphological changes became apparent. The formation of characteristic elongated cellular structures was observed in cells cultured under differentiation
conditions. The morphological changes were accompanied by the changes in the expression of early (MyoD) and late (myogenin) muscles differentiation markers. The
expression of MyoD decreased to an undetectable level during the differentiation process. At the same time, the level of myogenin increased during the first 8 days (middle
panel). Western blot analysis of phospho-MET and total MET showed significantly reduced signals for these proteins after 10 days of differentiation, in addition to a slight
decrease of total Src protein. GAPDH was used as a loading control (right panel). The expression of the MET and CXCR4 receptors was evaluated in both undifferentiated and
differentiated RH30 cell lines. (b) RT-PCR analysis of MET and CXCR4 receptor expression. The significant downregulation of the MET and CXCR4 receptors was observed
at the mRNA level (left panel). Flow cytometry analysis of CXCR4 receptor expression in RH30 cells. The expression of the CXCR4 receptors decreased in a time-dependent
manner and was completely gone after 10 days of differentiation (right panel). (c) Chemotactic assay of RH30 cells. The differentiated cells were subjected to a chemotaxis
assay towards SDF-1 and human HGF gradients. A strong inhibition in the migration properties to both chemoattractants was observed. The experiment was repeated three
times with similar results. Bar¼ 50mm; *Po0.05
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re-expression of microRNA-206 in human RMS cells pro-
moted myogenic differentiation and blocked tumor growth in
xenografted mice by switching the global mRNA expression
profile to one resembling mature muscle. Forced induction of
miR-206 expression at the onset of normal myogenesis
promotes this differentiation by modulating more than
700 genes, including theMET receptor, causingMET receptor
downregulation in murine satellite cells and two RMS cell lines
(ERMSRH4 and ARMSRH18),34 and the authors speculated
that the differentiation process might be connected to MET
receptor expression. A different study showed that both miR1
andmiR133a induce differentiation in embryonal RMS, but not
in alveolar RMS.48 These authors speculated that the
presence of the PAX3-FKHR fusion gene might be respon-
sible for the inhibition of tumor cell differentiation. In our study,
the downregulation of MET expression was sufficient to
induce the differentiation of ARMS, suggesting that out of
those 700 genes, the deregulated MET receptor gene may be
the most important factor in blocking the differentiation RMS
cells. The fact that the downregulation of the MET receptor,
regardless of the mechanism, restores the differentiation
ability of these cells indicates there is a connection and
dependency between the downstream signaling pathways of
HGF-MET and other genes associated with differentiation.
Differentiation therapy using an ATRA agent was found to
be beneficial for the treatment of APL patients,32 establishing
a paradigm for the use of differentiation therapy in the
treatment of other tumors. Because several different studies
have linked the development and progression of RMS tumors
with a defect in early muscle or mesenchymal cells,49 we
postulate that the induction of RMS cell differentiation (using,
for example, MET receptor blockers and inhibitors, similarly to
ATRA) could be a new therapeutic strategy for advanced,
aggressive, and metastatic RMS tumors.
Materials and Methods
Cell lines. C2C12 cells (ATCC), RMS cell lines used in this study (SMS-
CTRERMS, RH30, CW9019ARMS) (kindly provided by Dr. PJ Houghton (Center
for Childhood Cancer, Columbus, OH, USA)) were maintained in DMEM
(Gibco,BRL Grand Island, NY, USA) supplemented with 10% heat-inactivated FBS
(Gibco, BRL Grand Island, NY, USA), 100 IU/ml penicillin, 10 mg/ml streptomycin
(Gibco, BRL Grand Island, NY, USA). Cells were cultured at 37 1C, 5% CO2 and
95% humidity. They were split usually twice a week with medium change. RMS
cells were transduced directly with viral supernatants and subsequently selected
with blasticidin (Invitrogen, Carlsbad, CA, USA) as has been shown.25 MET
shRNA sequence 50-AGUCCGAGAUGAAUGUGAAtt-30 has been designed with
use of available algorithm from Ambion http://www.ambion.com/techlib/misc/siRNA
finder.html.
Reagents. Met Inhibitor SU11274: (3Z)-N-(3-Chlorophenyl)-3-((3,5-dimethyl-4-
((4-methylpiperazin-1-yl) carbonyl) -1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-
dihydro-1H-indole-5-sulfonamide (Calbiochem, Darmstadt, Germany) was dis-
solved in DMSO and used at a concentration of 5 mM.50–52
Differentiation protocol. RH30 and CW9019 cells were subjected to
differentiation by culturing in the differentiation medium composed of DMEM
(Gibco BRL, Grand Island, NY, USA), 2% horse serum (HS) (Gibco BRL, Grand
Island, NY, USA) and 100 nM TPA (Sigma, St Louis, MO, USA).10,53 The cells
were cultured in this medium for 4, 8 and 10 days, and subsequently used in
appropriate experiments. C2C12 cells were subjected to the differentiation and
myotube formation by culturing in the differentiation medium composed of DMEM
(Gibco BRL, Grand Island, NY, USA) and 10% HS (Gibco BRL, Grand Island, NY,
USA), according to ATCC recommendations.
Flow cytometry. For evaluation of CXCR4 receptor expression, cells were
incubated with monoclonal PE-labeled anti-human CD184 (CXCR4) antibody,
clone 12G5 (BD Pharmingen, San Diego, CA, USA).26 For detection of MET
receptor expression, mononclonal FITC-labeled anti-human HGFR/c-MET anti-
body, clone 95106 (R&D) was used. Briefly, 1 105 cells suspended in 100 ml of
staining buffer (PBS, 2% FBS) were added to a test tube containing the
appropriate amount of each antibody. The cells were incubated in the dark for
30min at 4 1C. The stained cells were then washed and collected using a
FACSCanto cytometer (Becton Dickinson, San Jose, CA, USA) and finally
analyzed with FACS Diva software (Becton Dickinson).
RNA extraction and reverse transcription. The total RNA was
extracted using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) followed by
DNAse treatment (Promega, Madison, WI, USA). The reverse polymerase
transcription was performed using MMLV reverse transcriptase (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol.
Quantitative real-time PCR (qRT-PCR) analysis. Gene expression
was determined by qRT-PCR analysis on ABI PRISM 7300 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA) using a commercially
available TaqMAN PCR Master Mix (Applied Biosystems, Foster City, CA, USA).
The primers sequences were as follows: Human: GAPDH Hs99999905_m1, MET
(Hs01565589_m1), CXCR4 (Hs00237052_m1), MYOSTATIN (Hs00976237_m1),
MYOGENIN (Hs01032275_m1), MYHC2 (Hs00430042_m1), mouse:
GAPDH (Mm99999915_g1), MYOSTATIN (Mn01254559_m1), MYOGENIN
(Mn00446195_g1), MYHC2 (Mn01332564_m1); all from (Applied Biosystems,
Foster City, CA, USA). The mRNA expression level for all samples was normalized
to the housekeeping gene GAPDH. 2DDCT method allowed to calculate relative
expression of the genes.
Western blot and Immunoprecipitation. Western blots were done on
extracts prepared from cells as previously described.25 Briefly, RMS cells were
lysed (for 10min) on ice in M-Per lysing buffer (Pierce Rockford, IL, USA)
containing protease and phosphatase inhibitors (Sigma, St. Louis, MO, USA).
Subsequently, the extracted proteins were separated on a 12% sodium dodecyl
sulfate–PAGE gel, and the fractionated proteins were transferred into a PVDF
membrane (BioRad; BioRad Laboratories, Hecules, CA, USA). Phosphorylation of
MET was detected by anti-phospho-MET (Tyr1234/1235) (Cell Signaling, Danvers,
MA, USA) antibody. The phosphorylation of AKT and MAPK was assessed using
primary rabbit anti-phospho-AKT (Ser 473) and mouse anti-phospho-MAPK
(Thr202/Tyr204) antibodies both from Cell Signaling Danvers, MA, USA. The
phosphorylation of Src was detected by monoclonal mouse anti-phospho-Src
(Tyr416) antibody (clone 9A6; EMD Millipore Corp., Billerica, MA, USA) and the
total level of Src was determined by monoclonal mouse anti-Src (clone GD11).
The total level of MET and MyoD proteins was assessed using primary rabbit
polyclonal antibodies (Santa Cruz Biotech., Santa Cruz, CA, USA), the expression
of myogenin was assessed using primary mouse monoclonal antibody (Santa
Cruz Biotech., Santa Cruz, CA, USA), and they were subsequently detected with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit or goat anti-mouse IgG
secondary antibodies (Santa Cruz Biotech., Santa Cruz, CA, USA). The
membranes were developed with an enhanced chemiluminescence (ECL) reagent
(Amersham Life Sciences, Little Chalfont, UK), dried and subsequently exposed to
the HyperFilm (Amersham Life Sciences, Little Chalfont, UK) or were imaged by
Gel Logic Imaging System 1500 (Kodak; Molecular Imaging System Corestea
Health Inc., Rochester, NY, USA). An equal loading in the lanes was evaluated by
probing with an rabbit anti-GAPDH, rabbit anti-AKT, and mouse anti-MAPK
antibody all from Cell Signaling, Danvers, MA, USA. Phospho-MET
was immunoprecipitated from 1mg of protein extracts with anti-MET rabbit
polyclonal antibody (MET C-12: sc-10; Santa Cruz, CA, USA). Corresponding
blots were developed with anti-phospho-MET (Tyr1234/1235) (Cell Signaling,
Danvers, MA, USA).
Chemotaxis assay. The directional movement of cells toward the HGF
gradient was evaluated using modified Boyden’s chamber with 8-mm pore
polycarbonate membrane inserts (Transwell; Costar Corning, Cambrige, MA,
USA). The cells detached with 0.25% trypsin were seeded into the upper chamber
of an insert at a density of 2.5 104 in 100ml. The lower chamber was filled with a
prewarmed medium containing hHGF (20 ng/ml), mouse HGF (50, 100, 200 ng/ml)
both from R&D System, Minneapolis, MN, USA or SDF-1 (100 ng/ml) (PeproTech
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EC, London, UK). 0.5% BSA DMEM medium was used as a negative control.
Inserts were removed from the transwell after 24 h and the cells were fixed with
methanol. The cells that did not migrate were scraped off with cotton wool from the
upper membrane and cells that had transmigrated to the lower side of the
membrane were stained with Wright solution (Merck, Darmstadt, Germany) and
counted under high power field (HPF) with inverted microscope (Olympus IX70,
Olympus Optical Co., LTD., Tokyo, Japan). Five fields were counted each time
and the mean number of cells per HPF was calculated. Chemotaxis assay was
performed at least three times, always in duplicates.
Invasion assay. GFR Matrigel invasion inserts (BD Pharmingen, San Diego,
CA, USA) were rehydrated with DMEM for 2 h and transferred to the wells
containing medium with chemoattractant (mouse HGF 50–200 ng/ml) or medium
alone (DMEM with 0.5% BSA) as a control. The cells were then harvested by
trypsinization, washed, resuspended in DMEM medium containing 0.5% BSA, and
seeded at a density of 2.5 104 in 0.5 ml to the inside of the inserts. After 24 h,
the cells that invaded the Matrigel were counted on the undersides of filters
following fixation and staining with Wright solution. The experiments were carried
out twice in duplicates.
Long- and short-term murine models. For long-term-assay 5 106,
RMS cells were injected subcutaneously into 6–8 weeks NOD-SCID mice. After 30
days the mice were killed and their tumors and BM cells harvested. The tumors
were weighed and fixed in formalin. Immunohistochemical evaluation was
performed using primary mouse monoclonal antibodies from DakoCytomation,
Denmark, UK, anti-Ki67 (clon MIB-1; 1 : 75), anti-desmina (clon D33; 1 : 50) and
EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse (DakoCytomation,
Denmark, UK).54 Each experimental group comprised 5–6 animals and all the
experiments were repeated three times.
The appearance of RMS cells in the bone marrow, as a metastasis from ectopic
injection, was evaluated by real-time PCR using human GAPDH specific primers-
probe set (Hs99999905_m1; Applied Biosystems, Foster City, CA, USA) as a
marker of human RMS cells.55 A control experiment showed no cross-reactivity with
murine GAPDH (Mm99999915_g1; Applied Biosystems, Foster City, CA, USA). In
order to study the potential of these cells to metastasize into BM cavities, 30 days
after injection, the cells were isolated from two of the legs of each mouse and their
presence was examined using qRT-PCR to distinguish between human and murine
cells. Next, in order to confirm the presence of human RMS cells in the BM of
injected mice, the bones were fixed in formalin and stained immunohistochemically,
using monoclonal mouse anti-vimentin antibody (clone v9; 1 : 100) (DakoCytoma-
tion, Denmark, UK). In order to visualize human cells in the BM in short-term
engraftment, RMS cells were labeled with 9 mM DiI (Molecular Probes) for 30min at
37 1C in PBS supplemented with glucose (1mg/ml) and injected intravenously
(1 106/mouse). After 24 h cells isolated from mice legs were analyzed using
fluorescent microscope (Olympus).
Statistical analysis. Statistical analysis was performed using a one-way
non-paired Student’s t-test with Microsoft Excel or test w2 with post-hoc Fisher’s
test using Graphpad software (GraphPad Software Inc., La Jolla, CA, USA).
P-values lower than 0.05 were considered as significant. The data from three
separate experiments was analyzed.
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